Update on immunopathogenesis and immunotherapy in multiple sclerosis

References

• Multiple Sclerosis International FederationAtlas of MS Database Available from: http://www.atlasofms.orgAccessed September 19, 2012
   Google Scholar
• SadovnickADEbersGCDymentDARischNJEvidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study GroupLancet1996347172817308656905
   PubMed Web of Science ®Google Scholar
• AscherioAMungerKLEnvironmental risk factors for multiple sclerosis. Part I: the role of infectionAnn Neurol20076128829917444504
   PubMed Web of Science ®Google Scholar
• AscherioAMungerKLEnvironmental risk factors for multiple sclerosis. Part II: noninfectious factorsAnn Neurol20076150451317492755
   PubMed Web of Science ®Google Scholar
• SawcerSHellenthalGPirinenMGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature201147621421921833088
   PubMed Web of Science ®Google Scholar
• AscherioAMungerKLSimonKCVitamin D and multiple sclerosisLancet Neurol2010959961220494325
   PubMed Web of Science ®Google Scholar
• HughesLESmithPABonellSCross-reactivity between related sequences found in Acinetobacter sp, Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosisJ Neuroimmunol200314410511514597104
   PubMed Web of Science ®Google Scholar
• SwanborgRHWhittum-HudsonJAHudsonAPInfectious agents and multiple sclerosis – are Chlamydia pneumoniae and human herpes virus 6 involved?J Neuroimmunol20031361812620637
   PubMed Web of Science ®Google Scholar
• HemmerBArchelosJJHartungHPNew concepts in the immunopathogenesis of multiple sclerosisNat Rev Neurosci2002329130111967559
   PubMed Web of Science ®Google Scholar
• FujinamiRSOldstoneMBAmino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunityScience1985230104310452414848
   PubMed Web of Science ®Google Scholar
• AichelePBachmannMFHengartnerHZinkernagelRMImmunopathology or organ-specific autoimmunity as a consequence of virus infectionImmunol Rev199615221458930666
   PubMed Web of Science ®Google Scholar
• WucherpfennigKWStromingerJLMolecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic proteinCell1995806957057534214
   PubMed Web of Science ®Google Scholar
• O’ConnorKCBar-OrAHaflerDAThe neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesisJ Clin Immunol200121819211332657
   PubMed Web of Science ®Google Scholar
• GayFWDryeTJDickGWEsiriMMThe application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesionBrain1997120Pt 8146114839278635
   PubMed Web of Science ®Google Scholar
• HauserSLBhanAKGillesFKempMKerrCWeinerHLImmunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesionsAnn Neurol1986195785873524414
   PubMed Web of Science ®Google Scholar
• LucchinettiCBruckWParisiJScheithauerBRodriguezMLassmannHHeterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelinationAnn Neurol20004770771710852536
   PubMed Web of Science ®Google Scholar
• FergusonBMatyszakMKEsiriMMPerryVHAxonal damage in acute multiple sclerosis lesionsBrain1997120Pt 33933999126051
   PubMed Web of Science ®Google Scholar
• BruckWKuhlmannTStadelmannCRemyelination in multiple sclerosisJ Neurol Sci200320618118512559508
   PubMed Web of Science ®Google Scholar
• LassmannHBruckWLucchinettiCRodriguezMRemyelination in multiple sclerosisMult Scler199731331369291167
   PubMed Web of Science ®Google Scholar
• BarnettMHPrineasJWRelapsing and remitting multiple sclerosis: pathology of the newly forming lesionAnn Neurol20045545846815048884
   PubMed Web of Science ®Google Scholar
• SakaguchiSNaturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-selfNat Immunol2005634535215785760
   PubMed Web of Science ®Google Scholar
• Hvilsted NielsenHToft-HansenHLambertsenKLOwensTFinsenBStimulation of adult oligodendrogenesis by myelin-specific T cellsAm J Pathol20111792028204121872562
   PubMed Web of Science ®Google Scholar
• NeumannHMedanaIMBauerJLassmannHCytotoxic T lymphocytes in autoimmune and degenerative CNS diseasesTrends Neurosci20022531331912086750
   PubMed Web of Science ®Google Scholar
• TuohyVKYuMWeinstock-GuttmanBKinkelRPDiversity and plasticity of self recognition during the development of multiple sclerosisJ Clin Invest199799168216909120012
   PubMed Web of Science ®Google Scholar
• UccelliAAloisiFPistoiaVUnveiling the enigma of the CNS as a B-cell fostering environmentTrends Immunol20052625425915866238
   PubMed Web of Science ®Google Scholar
• StorchMKPiddlesdenSHaltiaMIivanainenMMorganPLassmannHMultiple sclerosis: in situ evidence for antibody- and complement-mediated demyelinationAnn Neurol1998434654719546327
   PubMed Web of Science ®Google Scholar
• SrivastavaRAslamMKalluriSRPotassium channel KIR4.1 as an immune target in multiple sclerosisN Engl J Med201236711512322784115
   PubMed Web of Science ®Google Scholar
• MorandiBBramantiPBonaccorsiIRole of natural killer cells in the pathogenesis and progression of multiple sclerosisPharmacol Res2008571518182304
   PubMed Web of Science ®Google Scholar
• ColomboMDonoMGazzolaPAccumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patientsJ Immunol20001642782278910679121
   PubMed Web of Science ®Google Scholar
• KeeganMKonigFMcClellandRRelation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeLancet200536657958216099294
   PubMed Web of Science ®Google Scholar
• HowellOWReevesCANicholasRMeningeal inflammation is widespread and linked to cortical pathology in multiple sclerosisBrain20111342755277121840891
   PubMed Web of Science ®Google Scholar
• LucchinettiCFPopescuBFBunyanRFInflammatory cortical demyelination in early multiple sclerosisN Engl J Med20113652188219722150037
   PubMed Web of Science ®Google Scholar
• No authors listedInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• No authors listedPlacebo-controlled multicentre randomised trial of interferon-beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon-beta-1b in secondary progressive MSLancet1998352149114979820296
   PubMed Web of Science ®Google Scholar
• PanitchHMillerAPatyDWeinshenkerBNorth American Study Group on Interferon beta-1b in Secondary ProgressiveMSInterferon beta-1b in secondary progressive MS: results from a 3-year controlled studyNeurology2004631788179515557491
   PubMed Web of Science ®Google Scholar
• KapposLWeinshenkerBPozzilliCInterferon beta-1b in secondary progressive MS: a combined analysis of the two trialsNeurology2004631779178715557490
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon-beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study GroupN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon-beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• Ann MarrieRRudickRADrug insight: interferon treatment in multiple sclerosisNat Clin Pract Neurol20062344416932519
   PubMedGoogle Scholar
• ChenMChenGDengSLiuXHuttonGJHongJIFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosisJ Neuroimmunol2012242394622112394
   PubMed Web of Science ®Google Scholar
• TeitelbaumDWebbCBreeMMeshorerAArnonRSelaMSuppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymerClin Immunol Immunopathol197432562624141659
   PubMedGoogle Scholar
• TeitelbaumDAharoniRArnonRSelaMSpecific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1Proc Natl Acad Sci U S A198885972497282462252
   PubMed Web of Science ®Google Scholar
• GranBTranquillLRChenMMechanisms of immunomodulation by glatiramer acetateNeurology2000551704171411113226
   PubMed Web of Science ®Google Scholar
• TeitelbaumDFridkis-HareliMArnonRSelaMCopolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responsesJ Neuroimmunol1996642092178632064
   PubMed Web of Science ®Google Scholar
• Ben-NunAMendelIBakimerRThe autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced diseaseJ Neurol1996243S14S228965116
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMWolinskyJSEuropean/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study GroupAnn Neurol20014929029711261502
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet20093741503151119815268
   PubMed Web of Science ®Google Scholar
• LalivePHNeuhausOBenkhouchaMGlatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of actionCNS Drugs20112540141421476611
   PubMed Web of Science ®Google Scholar
• HaasJKorporalMBalintBFritzschingBSchwarzAWildemannBGlatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosisJ Neuroimmunol200921611311719646767
   PubMed Web of Science ®Google Scholar
• HongJLiNZhangXZhengBZhangJZInduction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3Proc Natl Acad Sci U S A20051026449645415851684
   PubMed Web of Science ®Google Scholar
• HartungHPGonsetteRKonigNMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialLancet20023602018202512504397
   PubMed Web of Science ®Google Scholar
• BielekovaBBeckerBLMonoclonal antibodies in MS: mechanisms of actionNeurology201074Suppl 1S31S4020038761
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon-beta-1a for relapsing multiple sclerosisN Engl J Med200635491192316510745
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med20123661870188022591293
   PubMed Web of Science ®Google Scholar
• O’ConnorPWGoodmanAKapposLDisease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology2011761858186521543733
   PubMed Web of Science ®Google Scholar
• BrinkmannVBillichABaumrukerTFingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNat Rev Drug Discov2010988389721031003
   PubMed Web of Science ®Google Scholar
• KowarikMCPellkoferHLCepokSDifferential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MSNeurology2011761214122121464424
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med201036238740120089952
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEuropean Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/04/human_pha_detail_000059.jsp&mid=WC0b01ac058001d126Accessed September 15, 2012
   Google Scholar
• US Food Drug AdministrationFDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htmAccessed September 15, 2012
   Google Scholar
• JonesJLColesAJCampath-1H treatment of multiple sclerosisNeurodegener Dis20085273118075272
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab versus interferon-beta-1a in early multiple sclerosisN Engl J Med20083591786180118946064
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLCARE-MS I investigatorsAlemtuzumab versus interferon-beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trialLancet20123801819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLCARE-MS II investigatorsAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase 3 trialLancet20123801829183923122650
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med200835867668818272891
   PubMed Web of Science ®Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol20096646047119847908
   PubMed Web of Science ®Google Scholar
• KapposLLiDCalabresiPAOcrelizumab in relapsing-remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trialLancet20113781779178722047971
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis Available from: http://www.clinicaltrials.gov/show/NCT01247324 and http://www.clinicaltrials.gov/show/NCT01412333Accessed September 23, 2012
   Google Scholar
• ClinicalTrials.govA study of ocrelizumab in patients with primary progressive multiple sclerosis Available from: http://www.clinicaltrials.gov/show/NCT01194570Accessed September 23, 2012
   Google Scholar
• Soelberg SorensenPDrulovicJHavrdovaELisbySGraffOShackelfordSMagnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) – 24-week results of a Phase II study [abstract]Mult Scler201016Suppl 10S37S38
   Google Scholar
• ZouLPAbbasNVolkmannISuppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissueNeuropharmacology20024273173911985832
   PubMed Web of Science ®Google Scholar
• BrunmarkCRunstromAOhlssonLThe new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJ Neuroimmunol200213016317212225898
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb studyLancet20083712085209218572078
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med20123661000100922417253
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govBRAVO study: laquinimod double blind placebo controlled study in RRMS patients with a rater blinded reference arm of interferon β-1a (Avonex^®) Available from: http://clinicaltrials.gov/show/NCT00605215Accessed September 17, 2012
   Google Scholar
• WilmsHSieversJRickertURostami-YazdiMMrowietzULuciusRDimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammationJ Neuroinflammation201073020482831
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb studyLancet20083721463147218970976
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med20123671087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med20123671098110722992073
   PubMed Web of Science ®Google Scholar
• SchorlemmerHUMilbertUZeitterDHaunGWunschelMBartlettRRCell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomideInflamm Res199948Suppl 2S115S11610667841
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med20113651293130321991951
   PubMed Web of Science ®Google Scholar
• KapposLComiGConfavreuxCThe efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a Phase III, placebo-controlled studyAbstract presented at the 28th Congress of the European Committee for Treatment and Research in Multiple SclerosisOctober 10–13, 2012Lyon, France
   Google Scholar
• ClinicalTrials.govAn Efficacy Study of Teriflunomide in Patients with Relapsing Multiple Sclerosis (TOWER) Available from: http://clinicaltrials.gov/show/NCT00751881Accessed September 17, 2012
   Google Scholar
• ClinicalTrials.govA study comparing the effectiveness and safety of Teriflunomide and Interferon Beta-1a in Patients with Relapsing Multiple Sclerosis (TENERE) Available from: http://clinicaltrials.gov/show/NCT00883337Accessed September 17, 2012
   Google Scholar
• ClinicalTrials.govPhase III study with Teriflunomide Versus Placebo in Patients with First Clinical Symptom of Multiple Sclerosis (TOPIC) Available from: http://clinicaltrials.gov/show/NCT00622700Accessed September 17, 2012
   Google Scholar
• WynnDKaufmanMMontalbanXDaclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon-betaLancet Neurol2010938139020163990
   PubMed Web of Science ®Google Scholar
• GiovannoniGGoldRSelmajKA randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trialAbstract presented at the 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple SclerosisOctober 19–22, 2011Amsterdam, The Netherlands
   Google Scholar
• ClinicalTrials.govEfficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients with Relapsing-Remitting Multiple Sclerosis (DECIDE) Available from: http://clinicaltrials.gov/show/NCT01064401Accessed September 17, 2012
   Google Scholar
• ConnickPKolappanMCrawleyCAutologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label Phase 2a proof-of-concept studyLancet Neurol20121115015622236384
   PubMed Web of Science ®Google Scholar
• NashRAHuttonGJRackeMKTreatment of severe relapsing-remitting multiple sclerosis with high-dose immunosuppressive therapy and autologous hematopoietic cell trans plantation: early results of the HALT MS clinical trial (Immune Tolerance Network: ITN033AI)ASH Annual Meeting Abstracts20111183075
   Google Scholar
• BurtRKLohYCohenBAutologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II studyLancet Neurol2009824425319186105
   PubMed Web of Science ®Google Scholar
• MancardiGLMurialdoARossiPAutologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosisMult Scler20051136737115957523
   PubMed Web of Science ®Google Scholar
• KimiskidisVSakellariITsimourtouVAutologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcomeMult Scler20081427828317942513
   PubMed Web of Science ®Google Scholar
• FagiusJLundgrenJObergGEarly highly aggressive MS successfully treated by hematopoietic stem cell transplantationMult Scler20091522923718805841
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govHematopoietic stem cell therapy for patients with inflammatory multiple sclerosis failing interferon: a randomized study Available from: http://clinicaltrials.gov/show/NCT00273364Accessed January 14, 2013
   Google Scholar